SAGE-217


SAGE Therapeutics Inc (SAGE) Wins Price Target Hike on Back of Encouraging MDD Data

Canaccord’s John Newman now sees almost 18% in upside potential for SAGE following a big clinical home run in major depressive disorder.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts